Emily Markey
Huntersville, NCNPI 1225668601
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 509 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations.
Across 509 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Supernus Pharmaceuticals, Inc.$2K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Axsome Therapeutics, Inc.$802
- plus $4K from 22 others
What the payments were for
- Food & beverage$11,60098%
- Education$2932%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 70 | $1,841 |
| Teva Pharmaceuticals USA, Inc. | 65 | $1,568 |
| Supernus Pharmaceuticals, Inc. | 70 | $1,562 |
| AbbVie | 65 | $1,325 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 43 | $1,011 |
| Axsome Therapeutics, Inc. | 26 | $802 |
| Alkermes, Inc. | 32 | $695 |
| E.r. Squibb & Sons, L.L.C. | 16 | $618 |
| Sunovion Pharmaceuticals Inc. | 14 | $329 |
| Neurocrine Biosciences, Inc. | 14 | $256 |
| Vanda Pharmaceuticals Inc. | 14 | $255 |
| Lundbeck LLC | 17 | $239 |
| Corium, LLC | 8 | $213 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $207 |
| Ironshore Pharmaceuticals Inc. | 8 | $177 |
| Braeburn Inc. | 5 | $167 |
| Janssen Scientific Affairs, LLC | 2 | $149 |
| Johnson & Johnson | 5 | $140 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $70 |
| Indivior Inc. | 4 | $69 |
| Novo Nordisk | 2 | $40 |
| Noven Therapeutics, LLC | 2 | $38 |
| Tris Pharma Inc | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Luye Pharma (USA) Ltd. | 1 | $20 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Almatica Pharma LLC | 1 | $12 |
| Neos Therapeutics, LP | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.